Glenmark gets FDA nod for generic Olux-E Foam
Glenmark has received the Food and Drug Administration's clearance for clobetasol propionate foam (emulsion formulation), in a strength of 0.05%
The product is the generic of Mylan's Olux-E Foam, 0.05%.
Olux-E Foam, 0.05% had a market value of approximately $11.1 million, for the 12 month period ending July 2019, according to IQVIA.
Olux foam is a corticosteroid indicated for treatment of moderate to severe plaque psoriasis of the scalp and mild to moderate plaque psoriasis of non-scalp regions of the body excluding the face and intertriginous areas in patients 12 years and older.
The product is the generic of Mylan's Olux-E Foam, 0.05%.
Olux-E Foam, 0.05% had a market value of approximately $11.1 million, for the 12 month period ending July 2019, according to IQVIA.
Olux foam is a corticosteroid indicated for treatment of moderate to severe plaque psoriasis of the scalp and mild to moderate plaque psoriasis of non-scalp regions of the body excluding the face and intertriginous areas in patients 12 years and older.